Bortezomib, Liposomal Doxorubicin Hydrochloride, Dexamethasone, and Cyclophosphamide in Treating Patients With Multiple Myeloma That Relapsed After Autologous Stem Cell Transplant

NCT01078441 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

2

Enrollment

NIH

Sponsor class

Stopped The study was closed early due to weak accrual on June 26, 2012.

Conditions

Refractory Multiple Myeloma

Interventions

DRUG: liposomal doxorubicin
DRUG: bortezomib
DRUG: dexamethasone
DRUG: cyclophosphamide

Sponsor

National Cancer Institute (NCI)